Krystal Biotech Jefferies Global Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good morning, everyone. Welcome to 2026 Jefferies Global Healthcare Conference. My name is Roger Song, Senior Analyst, cover SMID cap biotech in the U.S. It is my great pleasure to have the fireside chat with Krystal Biotech. We have the CEO, Krish Krishnan, and the President R&D, Suma Krishnan.
Welcome. Thank you. Thanks for having us.
Excellent. Krish, why not you start with the state of art of the Krystal? A lot of good things happened in the past, in the entire 2026, and why you are excited about the future, particularly 2027.
That was going to be a long response.
It is okay, keep it short, and then we will have a detailed discussion.
I will. Look, first, the fundamental business, the commercial business has gone really well. The U.S. launch over the last three years has been really good, but not in terms of patient satisfaction, physician response to the drug. And we started venturing into outside ROW, and we were happy to make a great value proposition of VYJUVEK to patients in Japan. We were very pleased with the outcome of negotiations in Japan. And the same with in Europe. We have a few more countries to do, but we were happy with the value we were able to create for patients and physicians in Germany, and hopefully shortly in Spain and Italy.
Simply said, we feel more confident about the global VYJUVEK launch than we did at the time of the launch, as we learn more about the receptivity of the drug and the nature of the disease in different countries. That is one big aspect. The other aspect of Krystal that we are excited about are all the clinical programs, and we have many readouts upcoming in 2027 that Suma will talk in detail about. And all of these, a lot of them are unmet medical needs, whether it be in CF or VYJUVEK in the eye or NK. And more recently, you saw the data on Gorlin, and we have an upcoming data read on Hailey-Hailey. The skin franchise is getting very strong, and we are expanding into the lung and the eye. And hopefully, we are looking to get started on the aesthetics later in 2027.
The clinical program is good, but surrounding that is an infrastructure of CMC that we spent a lot of time early on in the evolution of the company that helps us get platform technology or whatever that helps support the clinical programs and help us accelerate them through approval. Last but not the least, the financial position of the company is very strong. We have a strong balance sheet. We have been EPS positive for, I can't even remember, eight, nine, 10 quarters, like for a while, only growing very nicely, so much so that we have the confidence that in spite of the R&D investment and looking at the commercial revenue line, we felt good about launching a stock buyback program, which you saw announced in last quarter.
Overall, there's a lot to be excited about, which would not happen without a remarkable team we have at Krystal, not just in the U.S., but worldwide right now.
That's a good CEO. You can summarize the whole company within that three minutes for me.
Yes, there's more to say.
Yes. Let's say, talk a little bit more details. You said it very clear, right? Krystal has the very strong commercial business, and also we have a very rich pipeline. Today, we have limited time. Maybe we'll focus on the commercial a little bit more, and also we're going to talk about the key aspects of the pipeline. Okay, so maybe start with VYJUVEK DEB in the commercial business. U.S., I think you added 30 new reimbursement last quarter or third quarter. Would that become the new run rate for 2027 because you're continuing to penetrate? Within that currently active patient, how many of them are actually on drug? Because you have the on and off treatment dynamic.
Look, I would not take one quarter results as the floor or the steady state going forward.
But it is true after three years of launch. One of the reasons we continue to report reimbursement approvals is to show there is pure demand. We are adding new patients on drug Q over Q over Q. If you look back over the last few quarters, it's been in the range of 30-40, a couple 35s. There's been some good quarters. While I would not take 30 as a floor or this is going to be the future run rate, we expect somewhere between 30 and 45 to be kind of like looking forward over time.
Okay. We are going out into the community.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
3 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
